Biox Biosciences, Novo, Sanofi and Merck & Co are all in line to exit the immuno-oncology therapy developer, which has filed for a $100m initial public offering.
Lava Therapeutics, a Netherlands-based cancer immunotherapy developer co-founded by drug development services provider Biox Biosciences, has filed for a $100m initial public offering on the Nasdaq Global Market.
Founded in 2016, Lava is developing bispecific antibody-based treatments intended to treat cancer by activating a subset of T cells known as the Vg9Vd2 cells, which can naturally separate tumour cells and healthy cells, and engaging them to kill cancer cells.
The company’s technology is based on research by Hans van…
